Monopar Therapeutics Inc. Weighted Average Basic Shares Outstanding, Pro Forma
Monopar Therapeutics Inc. (MNPR) reported Weighted Average Basic Shares Outstanding, Pro Forma of 3.50 million shares for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageBasicSharesOutstandingProForma · last filed 2024-08-09
- Monopar Therapeutics Inc. weighted average basic shares outstanding, pro forma for the quarter ending 2024-06-30 was 3.50M shares, a 30.47% increase year-over-year.
- Monopar Therapeutics Inc. weighted average basic shares outstanding, pro forma for the quarter ending 2023-06-30 was 2.69M shares.
| Period end | Weighted Average Basic Shares Outstanding, Pro Forma 3 month | Weighted Average Basic Shares Outstanding, Pro Forma 6 month |
|---|---|---|
| 2024-06-30 | 3.50M shares 10-Q · filed 2024-08-09 | 3.35M shares 10-Q · filed 2024-08-09 |
| 2023-06-30 | 2.69M shares 10-Q · filed 2024-08-09 | 2.65M shares 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |